Century Therapeutics (NASDAQ:IPSC) Given New $5.00 Price Target at Guggenheim

Century Therapeutics (NASDAQ:IPSC) had its price objective reduced by Guggenheim from $12.00 to $5.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued reports about the company. Piper Sandler dropped their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Century Therapeutics in a report on Wednesday, January 22nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $5.80.

Century Therapeutics Stock Performance

Shares of Century Therapeutics stock opened at $0.56 on Friday. Century Therapeutics has a fifty-two week low of $0.52 and a fifty-two week high of $4.78. The company has a market capitalization of $47.19 million, a P/E ratio of -0.30 and a beta of 1.75. The company has a fifty day moving average of $0.74 and a 200 day moving average of $1.16.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The business had revenue of $4.18 million during the quarter, compared to the consensus estimate of $0.67 million. Analysts forecast that Century Therapeutics will post -1.61 EPS for the current year.

Institutional Trading of Century Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Century Therapeutics by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 991,595 shares of the company’s stock valued at $1,002,000 after acquiring an additional 23,413 shares during the period. Jane Street Group LLC grew its holdings in Century Therapeutics by 166.2% during the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company’s stock valued at $49,000 after purchasing an additional 29,992 shares during the last quarter. Bank of America Corp DE raised its position in Century Therapeutics by 109.1% in the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares during the period. Marshall Wace LLP bought a new stake in Century Therapeutics in the fourth quarter worth about $36,000. Finally, Barclays PLC boosted its position in shares of Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after buying an additional 45,797 shares during the period. 50.20% of the stock is currently owned by institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.